Analyst consensus rating
Bolt Biotherapeutics Analyst Rating: Buy
BOLT is rated Buy by 3 analysts with a $29.00 target. As of 2026-08-26.
Direct answer
Bolt Biotherapeutics's consensus rating is Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $29.00.
Forecast evidence checked August 26, 2026.
Get free Bolt Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.85
- Average price target
- $29.00
- High price target
- $75.00
- Low price target
- $5.00
- Low target gap
- +29.9%
- Target upside
- +653.2%
- High target gap
- +1,848.1%
- Target range width
- 1,818.2%
- Consensus rating
- Buy
- Analysts
- 3
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bolt Biotherapeutics?
Bolt Biotherapeutics has a verified Buy consensus. The same dataset has an average price target of $29.00.
How far are Bolt Biotherapeutics's low and high targets from the recorded price?
The low target implies +29.9%, while the high target implies +1,848.1%.
How many analysts are included in Bolt Biotherapeutics's consensus?
The verified consensus includes 3 analysts.
How is Bolt Biotherapeutics's target upside or downside calculated?
The average target of $29.00 is divided by the recorded price of $3.85, then one is subtracted to produce +653.2%. This does not guarantee a future return.
When was Bolt Biotherapeutics's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.